CL2018000699A1 - Antibodies that bind interleukin 8 (il-8) and its uses - Google Patents

Antibodies that bind interleukin 8 (il-8) and its uses

Info

Publication number: CL2018000699A1
Authority: CL; Chile
Prior art keywords: antibodies; bind interleukin; interleukin; bind
Prior art date: 2015-09-18

Application number

CL2018000699A

Other languages

Spanish (es)

Inventor

Tomoyuki Igawa

Atsuhiko Maeda

Genki Nakamura

Masaru Muraoka

Original Assignee

Chugai Pharmaceutical Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-09-18

Filing date

2018-03-16

Publication date

2019-02-08

2018-03-16 Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd

2019-02-08 Publication of CL2018000699A1 publication Critical patent/CL2018000699A1/en

Links

XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 title 2
102000004890 Interleukin-8 Human genes 0.000 title 1
108090001007 Interleukin-8 Proteins 0.000 title 1
229940096397 interleukin-8 Drugs 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Pulmonology (AREA)
Biomedical Technology (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Dermatology (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Gastroenterology & Hepatology (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Vascular Medicine (AREA)
Endocrinology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Oncology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Physics & Mathematics (AREA)
Reproductive Health (AREA)

CL2018000699A 2015-09-18 2018-03-16 Antibodies that bind interleukin 8 (il-8) and its uses CL2018000699A1 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP2015185254		2015-09-18

Publications (1)

Publication Number	Publication Date
CL2018000699A1 true CL2018000699A1 (en)	2019-02-08

Family

ID=56738152

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2018000699A CL2018000699A1 (en)	2015-09-18	2018-03-16	Antibodies that bind interleukin 8 (il-8) and its uses

Country Status (21)

Country	Link
EP (1)	EP3350202A1 (en)
JP (5)	JP6266164B2 (en)
KR (4)	KR20230079500A (en)
CN (2)	CN113372443A (en)
AR (1)	AR105634A1 (en)
AU (1)	AU2016323088B2 (en)
CA (1)	CA2993423C (en)
CL (1)	CL2018000699A1 (en)
CO (1)	CO2018004056A2 (en)
CR (1)	CR20180217A (en)
IL (2)	IL258088B2 (en)
MA (1)	MA42808A (en)
MX (2)	MX2018003005A (en)
MY (1)	MY203894A (en)
PE (1)	PE20181336A1 (en)
PH (1)	PH12018500386B1 (en)
RU (1)	RU2728430C2 (en)
TW (5)	TWI814162B (en)
UA (1)	UA120981C2 (en)
WO (1)	WO2017046994A1 (en)
ZA (1)	ZA201800536B (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK2006381T3 (en)	2006-03-31	2016-02-22	Chugai Pharmaceutical Co Ltd	PROCEDURE FOR REGULATING ANTIBODIES BLOOD PHARMACOKINETICS
DK2202245T3 (en)	2007-09-26	2016-11-21	Chugai Pharmaceutical Co Ltd	A method of modifying an antibody isoelectric point VIA amino acid substitution in CDR
PT2708559T (en)	2008-04-11	2018-05-16	Chugai Pharmaceutical Co Ltd	Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
MX365235B (en)	2010-11-30	2019-05-28	Chugai Pharmaceutical Co Ltd	Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly.
US20150166654A1 (en)	2012-05-30	2015-06-18	Chugai Seiyaku Kabushiki Kaisha	Target tissue-specific antigen-binding molecule
TWI855488B (en)	2012-08-24	2024-09-11	日商中外製藥股份有限公司	Fcγriib-specific fc region variant
WO2014030750A1 (en)	2012-08-24	2014-02-27	中外製薬株式会社	MOUSE FcγRII-SPECIFIC Fc ANTIBODY
SG11201508170TA (en)	2013-04-02	2015-11-27	Chugai Pharmaceutical Co Ltd	Fc REGION VARIANT
TW202446953A (en)	2013-12-04	2024-12-01	日商中外製藥股份有限公司	Antigen-binding molecules and databases thereof whose antigen-binding ability varies in response to compound concentration
MX2017005774A (en)	2014-12-19	2017-07-28	Chugai Pharmaceutical Co Ltd	Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use.
SG11201706014PA (en)	2015-02-05	2017-08-30	Chugai Pharmaceutical Co Ltd	Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof
AR105634A1 (en) *	2015-09-18	2017-10-25	Chugai Pharmaceutical Co Ltd	ANTIBODIES THAT JOIN IL 8 AND ITS USES
JP7141336B2 (en)	2015-12-25	2022-09-22	中外製薬株式会社	Anti-myostatin antibodies and methods of use
KR102538749B1 (en)	2016-08-05	2023-06-01	추가이 세이야쿠 가부시키가이샤	Composition for prophylaxis or treatment of il-8 related diseases
SG10201607778XA (en)	2016-09-16	2018-04-27	Chugai Pharmaceutical Co Ltd	Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
KR102661320B1 (en) *	2017-06-05	2024-05-03	얀센 바이오테크 인코포레이티드	Surface charge manipulation method for generating bispecific antibodies
KR20200132938A (en)	2018-03-15	2020-11-25	추가이 세이야쿠 가부시키가이샤	Anti-dengue virus antibodies with cross-reactivity against Zika virus and methods of use
EP3835321A4 (en)	2018-08-10	2022-11-02	Chugai Seiyaku Kabushiki Kaisha	Anti-cd137 antigen-binding molecule and utilization thereof
JP7738480B2 (en) *	2019-04-19	2025-09-12	中外製薬株式会社	Antibodies and compositions for use in detecting or capturing polypeptides in a sample, and methods for detecting or capturing polypeptides in a sample
AU2020321368A1 (en) *	2019-07-30	2022-03-10	Mythic Therapeutics, Inc.	Antigen-binding protein constructs and uses thereof
EP4076663A1 (en)	2019-12-18	2022-10-26	F. Hoffmann-La Roche AG	Bispecific anti-ccl2 antibodies
EP4090736A4 (en) *	2020-01-11	2024-02-21	Yale University	Compositions and methods for treating, ameliorating, and/or preventing diseases or disorders caused by or associated with dnase1 and/or dnase1l3 deficiency
BR112022012467A2 (en)	2020-01-31	2022-09-06	Chugai Pharmaceutical Co Ltd	METHOD FOR PRODUCTION OF COMPOSITION CONTAINING COLOR SUPPRESSED POLYPEPTIDE
TWI895351B (en)	2020-02-12	2025-09-01	日商中外製藥股份有限公司	Anti-CD137 antigen binding molecules for the treatment of cancer
US20230348577A1 (en) *	2020-02-19	2023-11-02	Adivo Gmbh	Modified fc regions
US20230242635A1 (en) *	2020-04-17	2023-08-03	Zoetis Services Llc	Canine antibody variants
GB2595299B (en)	2020-05-21	2022-08-03	Mabsolve Ltd	Modified immunoglobulin FC regions
WO2022025030A1 (en) *	2020-07-28	2022-02-03	中外製薬株式会社	Prefilled syringe preparation with needle, provided with needle shield and including novel modified antibody
JP2023541816A (en) *	2020-08-27	2023-10-04	イノージ・セラピューティクス・コーポレイション	Methods and compositions for treating autoimmune diseases and cancer
EP4342984A4 (en)	2021-05-19	2025-04-23	Chugai Seiyaku Kabushiki Kaisha	Method for predicting the in vivo pharmaceutical kinetics of a molecule
CA3221735A1 (en)	2021-06-18	2022-12-22	F. Hoffmann-La Roche Ag	Bispecific anti-ccl2 antibodies

Family Cites Families (129)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4676980A (en)	1985-09-23	1987-06-30	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Target specific cross-linked heteroantibodies
US6548640B1 (en)	1986-03-27	2003-04-15	Btg International Limited	Altered antibodies
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
IL85035A0 (en)	1987-01-08	1988-06-30	Int Genetic Eng	Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
AU600575B2 (en)	1987-03-18	1990-08-16	Sb2, Inc.	Altered antibodies
WO1990005144A1 (en)	1988-11-11	1990-05-17	Medical Research Council	Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
DE3920358A1 (en)	1989-06-22	1991-01-17	Behringwerke Ag	BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
US5959177A (en)	1989-10-27	1999-09-28	The Scripps Research Institute	Transgenic plants expressing assembled secretory antibodies
US6075181A (en)	1990-01-12	2000-06-13	Abgenix, Inc.	Human antibodies derived from immunized xenomice
US6150584A (en)	1990-01-12	2000-11-21	Abgenix, Inc.	Human antibodies derived from immunized xenomice
KR100272077B1 (en)	1990-08-29	2000-11-15	젠팜인터내셔날,인코포레이티드	Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en)	1990-08-29	1998-06-23	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
WO1992009690A2 (en)	1990-12-03	1992-06-11	Genentech, Inc.	Enrichment method for variant proteins with altered binding properties
US5571894A (en)	1991-02-05	1996-11-05	Ciba-Geigy Corporation	Recombinant antibodies specific for a growth factor receptor
EP0590058B1 (en)	1991-06-14	2003-11-26	Genentech, Inc.	HUMANIZED Heregulin ANTIBODy
GB9114948D0 (en)	1991-07-11	1991-08-28	Pfizer Ltd	Process for preparing sertraline intermediates
WO1993006217A1 (en)	1991-09-19	1993-04-01	Genentech, Inc.	EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
FI941572L (en)	1991-10-07	1994-05-27	Oncologix Inc	Combination and method of use of anti-erbB-2 monoclonal antibodies
WO1993008829A1 (en)	1991-11-04	1993-05-13	The Regents Of The University Of California	Compositions that mediate killing of hiv-infected cells
AU3178993A (en)	1991-11-25	1993-06-28	Enzon, Inc.	Multivalent antigen-binding proteins
CA2124967C (en)	1991-12-17	2008-04-08	Nils Lonberg	Transgenic non-human animals capable of producing heterologous antibodies
ATE419355T1 (en)	1992-02-06	2009-01-15	Novartis Vaccines & Diagnostic	MARKER FOR CANCER AND BIOSYNTHETIC BINDING PROTEIN FOR IT
WO1994002602A1 (en)	1992-07-24	1994-02-03	Cell Genesys, Inc.	Generation of xenogeneic antibodies
WO1994029351A2 (en)	1993-06-16	1994-12-22	Celltech Limited	Antibodies
FR2707189B1 (en)	1993-07-09	1995-10-13	Gradient Ass	Method for treating combustion residues and installation for implementing said method.
US6048972A (en) *	1994-07-13	2000-04-11	Chugai Pharmaceutical Co., Ltd.	Recombinant materials for producing humanized anti-IL-8 antibodies
EP0770628B9 (en) *	1994-07-13	2007-02-28	Chugai Seiyaku Kabushiki Kaisha	Reconstituted human antibody against human interleukin-8
JP3865418B2 (en) *	1994-07-13	2007-01-10	中外製薬株式会社	Reconstituted human antibody against human interleukin-8
TW416960B (en) *	1994-07-13	2001-01-01	Chugai Pharmaceutical Co Ltd	Reshaped human antibody to human interleukin-8
CN1156460A (en) *	1994-07-13	1997-08-06	中外制药株式会社	Reconstituted human antibody against human interleukin-8
US5789199A (en)	1994-11-03	1998-08-04	Genentech, Inc.	Process for bacterial production of polypeptides
US5840523A (en)	1995-03-01	1998-11-24	Genetech, Inc.	Methods and compositions for secretion of heterologous polypeptides
US5731168A (en)	1995-03-01	1998-03-24	Genentech, Inc.	Method for making heteromultimeric polypeptides
JP4312259B2 (en)	1995-04-27	2009-08-12	アムジェンフレモントインク．	Human antibodies derived from immunized XenoMouse
EP0823941A4 (en)	1995-04-28	2001-09-19	Abgenix Inc	Human antibodies derived from immunized xenomice
US6267958B1 (en)	1995-07-27	2001-07-31	Genentech, Inc.	Protein formulation
IL129164A (en)	1996-09-26	2007-05-15	Chugai Pharmaceutical Co Ltd	Antibody against human parathormone related peptides
US6025158A (en) *	1997-02-21	2000-02-15	Genentech, Inc.	Nucleic acids encoding humanized anti-IL-8 monoclonal antibodies
FR2761994B1 (en)	1997-04-11	1999-06-18	Centre Nat Rech Scient	PREPARATION OF MEMBRANE RECEPTORS FROM EXTRACELLULAR BACULOVIRUSES
US6171586B1 (en)	1997-06-13	2001-01-09	Genentech, Inc.	Antibody formulation
US6040498A (en)	1998-08-11	2000-03-21	North Caroline State University	Genetically engineered duckweed
US6610833B1 (en)	1997-11-24	2003-08-26	The Institute For Human Genetics And Biochemistry	Monoclonal human natural antibodies
JP4460155B2 (en)	1997-12-05	2010-05-12	ザ・スクリプス・リサーチ・インステイチユート	Humanization of mouse antibodies
US6458355B1 (en) *	1998-01-22	2002-10-01	Genentech, Inc.	Methods of treating inflammatory disease with anti-IL-8 antibody fragment-polymer conjugates
JP4334141B2 (en)	1998-04-20	2009-09-30	グリカートバイオテクノロジーアクチェンゲゼルシャフト	Engineering glycosylation of antibodies to improve antibody-dependent cytotoxicity
US6737056B1 (en)	1999-01-15	2004-05-18	Genentech, Inc.	Polypeptide variants with altered effector function
BR0008758A (en)	1999-01-15	2001-12-04	Genentech Inc	Variants of parental polypeptides with altered effector function, polypeptides, isolated nucleic acid composition, vector, host cell, method for producing a polypeptide variant, method for treating a disorder in mammals and method for producing a variant fc region
CA2369292C (en)	1999-04-09	2010-09-21	Kyowa Hakko Kogyo Co. Ltd.	Method of modulating the activity of functional immune molecules
JP2003512821A (en)	1999-10-04	2003-04-08	メディカゴインコーポレイテッド	Methods for regulating transcription of exogenous genes
US7125978B1 (en)	1999-10-04	2006-10-24	Medicago Inc.	Promoter for regulating expression of foreign genes
US20030180714A1 (en)	1999-12-15	2003-09-25	Genentech, Inc.	Shotgun scanning
DK1272647T3 (en)	2000-04-11	2014-12-15	Genentech Inc	Multivalent antibodies and uses thereof
EP1332209B1 (en)	2000-09-08	2009-11-11	Universität Zürich	Collections of repeat proteins comprising repeat modules
EA013563B1 (en)	2000-10-06	2010-06-30	Киова Хакко Кирин Ко., Лтд.	A transgenic non-human animal, producing antibodies with modified sugar chains, a process for producing antibodies composition and a medicament comprising the antibodies
AU1325102A (en)	2000-10-16	2002-04-29	Phylos Inc	Protein scaffolds for antibody mimics and other binding proteins
US6596541B2 (en)	2000-10-31	2003-07-22	Regeneron Pharmaceuticals, Inc.	Methods of modifying eukaryotic cells
DK1354034T3 (en)	2000-11-30	2008-03-25	Medarex Inc	Transgenic transchromosomal rodents for the production of human antibodies
JP2005500018A (en)	2001-04-02	2005-01-06	アイデックファーマスーティカルズコーポレイション	Recombinant antibody coexpressed with GnTIII
US20030157561A1 (en)	2001-11-19	2003-08-21	Kolkman Joost A.	Combinatorial libraries of monomer domains
WO2003029462A1 (en)	2001-09-27	2003-04-10	Pieris Proteolab Ag	Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
US7771951B2 (en) *	2001-12-03	2010-08-10	Amgen Fremont Inc.	Antibody categorization based on binding characteristics
US20040132101A1 (en)	2002-09-27	2004-07-08	Xencor	Optimized Fc variants and methods for their generation
WO2003102580A1 (en) *	2002-05-31	2003-12-11	Biacore Ab	Method of coupling binding agents to a substrate surface
CA2488441C (en)	2002-06-03	2015-01-27	Genentech, Inc.	Synthetic antibody phage libraries
WO2003105757A2 (en)	2002-06-12	2003-12-24	Genencor International, Inc.	Methods and compositions for milieu-dependent binding of a targeted agent to a target
CA2499816C (en)	2002-09-27	2013-07-30	Xencor, Inc.	Optimized fc variants and methods for their generation
US7361740B2 (en)	2002-10-15	2008-04-22	Pdl Biopharma, Inc.	Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
PT1572744E (en)	2002-12-16	2010-09-07	Genentech Inc	Immunoglobulin variants and uses thereof
US20050079574A1 (en)	2003-01-16	2005-04-14	Genentech, Inc.	Synthetic antibody phage libraries
US7871607B2 (en)	2003-03-05	2011-01-18	Halozyme, Inc.	Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en)	2003-03-05	2006-05-18	Halozyme, Inc.	Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
TWI353991B (en)	2003-05-06	2011-12-11	Syntonix Pharmaceuticals Inc	Immunoglobulin chimeric monomer-dimer hybrids
JP4667383B2 (en)	2003-06-13	2011-04-13	バイオジェン・アイデック・エムエイ・インコーポレイテッド	Aglycosyl anti-CD154 (CD40 ligand) antibody and use thereof
US20070148170A1 (en)	2005-10-03	2007-06-28	Desjarlais John R	Fc Variants With Optimized Fc Receptor Binding Properties
AU2003271174A1 (en)	2003-10-10	2005-04-27	Chugai Seiyaku Kabushiki Kaisha	Double specific antibodies substituting for functional protein
AU2004284090A1 (en)	2003-10-24	2005-05-06	Avidia, Inc.	LDL receptor class A and EGF domain monomers and multimers
WO2005063816A2 (en)	2003-12-19	2005-07-14	Genentech, Inc.	Monovalent antibody fragments useful as therapeutics
CA2552788C (en)	2004-01-12	2013-09-24	Applied Molecular Evolution, Inc.	Fc region variants
US20050260711A1 (en)	2004-03-30	2005-11-24	Deepshikha Datta	Modulating pH-sensitive binding using non-natural amino acids
CA2561686C (en)	2004-03-31	2014-12-02	Genentech, Inc.	Humanized anti-tgf-beta antibodies
US7785903B2 (en)	2004-04-09	2010-08-31	Genentech, Inc.	Variable domain library and uses
BR122019012028B1 (en)	2004-04-13	2023-09-26	F. Hoffmann-La Roche Ag	ANTI-P-SELECTIN ANTIBODIES, NUCLEIC ACID MOLECULE, VECTOR, AND COMPOSITION
BRPI0510674A (en)	2004-07-15	2007-12-26	Xencor Inc	optimized fc variants
BRPI0514068B8 (en)	2004-08-04	2021-05-25	Applied Molecular Evolution Inc	anti-cd20 antibody, and, pharmaceutical composition
AU2005277567A1 (en)	2004-08-16	2006-03-02	Medimmune, Llc	Integrin antagonists with enhanced antibody dependent cell-mediated cytotoxicity activity
WO2006031370A2 (en)	2004-08-19	2006-03-23	Genentech, Inc.	Polypeptide variants with altered effector function
TWI380996B (en)	2004-09-17	2013-01-01	Hoffmann La Roche	Anti-ox40l antibodies
JO3000B1 (en)	2004-10-20	2016-09-05	Genentech Inc	Antibody Formulations.
AU2005335714B2 (en)	2004-11-10	2012-07-26	Macrogenics, Inc.	Engineering Fc antibody regions to confer effector function
EP1829961A4 (en)	2004-12-22	2008-06-04	Chugai Pharmaceutical Co Ltd	Method of preparing antibody by use of cell having its fucose transporter function inhibited
WO2006105338A2 (en)	2005-03-31	2006-10-05	Xencor, Inc.	Fc VARIANTS WITH OPTIMIZED PROPERTIES
JP5255435B2 (en)	2005-04-26	2013-08-07	メディミューン，エルエルシー	Regulation of antibody effector function by hinge domain manipulation
PL1919503T3 (en)	2005-08-10	2015-04-30	Macrogenics Inc	Identification and engineering of antibodies with variant fc regions and methods of using same
EP2465870A1 (en)	2005-11-07	2012-06-20	Genentech, Inc.	Binding polypeptides with diversified and consensus VH/VL hypervariable sequences
US20070237764A1 (en)	2005-12-02	2007-10-11	Genentech, Inc.	Binding polypeptides with restricted diversity sequences
AU2007212147A1 (en)	2006-02-03	2007-08-16	Medimmune, Llc	Protein formulations
DK2006381T3 (en) *	2006-03-31	2016-02-22	Chugai Pharmaceutical Co Ltd	PROCEDURE FOR REGULATING ANTIBODIES BLOOD PHARMACOKINETICS
WO2007134050A2 (en)	2006-05-09	2007-11-22	Genentech, Inc.	Binding polypeptides with optimized scaffolds
NZ574473A (en)	2006-08-02	2013-02-22	Uab Research Foundation	Methods and compositions related to soluble monoclonal variable lymphocyte receptors of defined antigen specificity
ES2399075T3 (en)	2006-08-30	2013-03-25	Genentech, Inc.	Multispecific Antibodies
CN103694349A (en) *	2006-09-08	2014-04-02	米迪缪尼有限公司	Humanized anti-cd19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
WO2008092117A2 (en)	2007-01-25	2008-07-31	Xencor, Inc.	Immunoglobulins with modifications in the fcr binding region
AU2008234248C1 (en)	2007-03-29	2015-01-22	Genmab A/S	Bispecific antibodies and methods for production thereof
US8337854B2 (en)	2007-04-04	2012-12-25	The United States Of America, As Represented By The Secretary, Department Of Health & Human Services	Monoclonal antibodies against dengue and other viruses with deletion in Fc region
CN100592373C (en)	2007-05-25	2010-02-24	群康科技(深圳)有限公司	Liquid crystal display panel driving device and driving method thereof
WO2009026117A2 (en) *	2007-08-16	2009-02-26	Glaxo Group Limited	Novel compounds
DK2202245T3 (en)	2007-09-26	2016-11-21	Chugai Pharmaceutical Co Ltd	A method of modifying an antibody isoelectric point VIA amino acid substitution in CDR
ES2742268T3 (en)	2007-12-26	2020-02-13	Xencor Inc	Fc variants with altered FcRn binding
PT2235064E (en)	2008-01-07	2016-03-01	Amgen Inc	Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
PT2708559T (en)	2008-04-11	2018-05-16	Chugai Pharmaceutical Co Ltd	Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
TWI667346B (en) *	2010-03-30	2019-08-01	中外製藥股份有限公司	Antibodies with modified affinity to fcrn that promote antigen clearance
CA2806252C (en)	2010-07-29	2019-05-14	Xencor, Inc.	Antibodies with modified isoelectric points
TR201802772T4 (en)	2010-11-17	2018-03-21	Chugai Pharmaceutical Co Ltd	Multi-specific antigen binding molecule with alternative function for the function of blood coagulation factor VIII.
MX365235B (en)	2010-11-30	2019-05-28	Chugai Pharmaceutical Co Ltd	Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly.
JP6043629B2 (en)	2011-01-07	2016-12-14	中外製薬株式会社	Methods for improving antibody physical properties
EP3604330A1 (en)	2011-02-25	2020-02-05	Chugai Seiyaku Kabushiki Kaisha	Fcgammariib-specific fc antibody
CA3186128A1 (en)	2011-09-30	2013-04-04	Chugai Seiyaku Kabushiki Kaisha	Antigen-binding molecule for promoting elimination of antigens
TW201326209A (en)	2011-09-30	2013-07-01	Chugai Pharmaceutical Co Ltd	Therapeutic antigen-binding molecule having an FcRn binding domain that promotes antigen clearance
IN2014CN03066A (en) *	2011-09-30	2015-08-07	Chugai Pharmaceutical Co Ltd
BR112014013081A2 (en)	2011-11-30	2020-10-20	Chugai Seiyaku Kabushiki Kaisha	drug-containing cell vehicle for formation of an immune complex
SG11201404751UA (en)	2012-02-09	2014-09-26	Chugai Pharmaceutical Co Ltd	Modified fc region of antibody
KR102475951B1 (en)	2012-02-24	2022-12-08	추가이 세이야쿠 가부시키가이샤	Antigen-binding molecule for promoting disappearance of antigen via FcγRIIB
WO2014030750A1 (en)	2012-08-24	2014-02-27	中外製薬株式会社	MOUSE FcγRII-SPECIFIC Fc ANTIBODY
TWI855488B (en)	2012-08-24	2024-09-11	日商中外製藥股份有限公司	Fcγriib-specific fc region variant
EP2970508A4 (en)	2013-03-15	2016-12-14	Permeon Biologics Inc	Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use
SG11201508170TA (en)	2013-04-02	2015-11-27	Chugai Pharmaceutical Co Ltd	Fc REGION VARIANT
SG11201706014PA (en) *	2015-02-05	2017-08-30	Chugai Pharmaceutical Co Ltd	Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof
AR105634A1 (en) *	2015-09-18	2017-10-25	Chugai Pharmaceutical Co Ltd	ANTIBODIES THAT JOIN IL 8 AND ITS USES

2016
- 2016-08-05 AR ARP160102414A patent/AR105634A1/en active IP Right Grant
- 2016-08-05 MY MYPI2018701018A patent/MY203894A/en unknown
- 2016-08-05 TW TW110145197A patent/TWI814162B/en active
- 2016-08-05 AU AU2016323088A patent/AU2016323088B2/en active Active
- 2016-08-05 CN CN202110827885.2A patent/CN113372443A/en active Pending
- 2016-08-05 TW TW112123388A patent/TW202342532A/en unknown
- 2016-08-05 CR CR20180217A patent/CR20180217A/en unknown
- 2016-08-05 PH PH1/2018/500386A patent/PH12018500386B1/en unknown
- 2016-08-05 CA CA2993423A patent/CA2993423C/en active Active
- 2016-08-05 TW TW113127633A patent/TW202446797A/en unknown
- 2016-08-05 EP EP16753718.2A patent/EP3350202A1/en active Pending
- 2016-08-05 MA MA042808A patent/MA42808A/en unknown
- 2016-08-05 WO PCT/JP2016/003616 patent/WO2017046994A1/en not_active Ceased
- 2016-08-05 CN CN201680054135.3A patent/CN108271372B/en active Active
- 2016-08-05 KR KR1020237017768A patent/KR20230079500A/en not_active Ceased
- 2016-08-05 RU RU2018113505A patent/RU2728430C2/en active
- 2016-08-05 JP JP2017508124A patent/JP6266164B2/en active Active
- 2016-08-05 UA UAA201804018A patent/UA120981C2/en unknown
- 2016-08-05 KR KR1020187032734A patent/KR102538745B1/en active Active
- 2016-08-05 PE PE2018000378A patent/PE20181336A1/en unknown
- 2016-08-05 TW TW105124915A patent/TWI621628B/en active
- 2016-08-05 KR KR1020257001597A patent/KR20250016474A/en active Pending
- 2016-08-05 TW TW107108073A patent/TWI751300B/en active
- 2016-08-05 IL IL258088A patent/IL258088B2/en unknown
- 2016-08-05 KR KR1020177037003A patent/KR101920175B1/en active Active
- 2016-08-05 MX MX2018003005A patent/MX2018003005A/en unknown
2017
- 2017-12-19 JP JP2017242615A patent/JP6903561B2/en active Active
2018
- 2018-01-25 ZA ZA2018/00536A patent/ZA201800536B/en unknown
- 2018-03-09 MX MX2022008781A patent/MX2022008781A/en unknown
- 2018-03-16 CL CL2018000699A patent/CL2018000699A1/en unknown
- 2018-04-16 CO CONC2018/0004056A patent/CO2018004056A2/en unknown
2021
- 2021-06-23 JP JP2021103813A patent/JP2021168658A/en active Pending
- 2021-08-04 IL IL285375A patent/IL285375B2/en unknown
2023
- 2023-09-25 JP JP2023159360A patent/JP2023164732A/en active Pending
2025
- 2025-06-02 JP JP2025091714A patent/JP2025120227A/en active Pending

Also Published As

Publication number	Publication date
KR20230079500A (en)	2023-06-07
CA2993423C (en)	2024-03-12
IL258088B2 (en)	2024-02-01
JP6266164B2 (en)	2018-01-31
RU2018113505A (en)	2019-10-18
MY203894A (en)	2024-07-23
MA42808A (en)	2018-07-25
CA2993423A1 (en)	2017-03-23
KR20180006452A (en)	2018-01-17
TW202214688A (en)	2022-04-16
MX2018003005A (en)	2018-04-11
NZ777634A (en)	2025-03-28
AU2016323088A1 (en)	2018-02-22
KR20180125036A (en)	2018-11-21
JP2017536800A (en)	2017-12-14
TWI751300B (en)	2022-01-01
CN108271372B (en)	2021-07-09
IL285375B2 (en)	2025-11-01
IL285375A (en)	2021-09-30
MX2022008781A (en)	2022-08-10
JP6903561B2 (en)	2021-07-14
TWI814162B (en)	2023-09-01
CR20180217A (en)	2018-05-03
TW201823272A (en)	2018-07-01
EP3350202A1 (en)	2018-07-25
CO2018004056A2 (en)	2018-11-30
KR20250016474A (en)	2025-02-03
PH12018500386B1 (en)	2024-01-05
JP2025120227A (en)	2025-08-15
ZA201800536B (en)	2019-07-31
AU2016323088B2 (en)	2020-12-10
CN108271372A (en)	2018-07-10
NZ739756A (en)	2025-03-28
JP2018085988A (en)	2018-06-07
AR105634A1 (en)	2017-10-25
PE20181336A1 (en)	2018-08-21
TWI621628B (en)	2018-04-21
RU2728430C2 (en)	2020-07-29
TW201712032A (en)	2017-04-01
KR101920175B1 (en)	2018-11-19
JP2023164732A (en)	2023-11-10
IL285375B1 (en)	2025-07-01
IL258088A (en)	2018-05-31
TW202342532A (en)	2023-11-01
CN113372443A (en)	2021-09-10
RU2018113505A3 (en)	2020-02-17
KR102538745B1 (en)	2023-06-01
UA120981C2 (en)	2020-03-10
WO2017046994A1 (en)	2017-03-23
PH12018500386A1 (en)	2018-09-03
TW202446797A (en)	2024-12-01
IL258088B1 (en)	2023-10-01
JP2021168658A (en)	2021-10-28
BR112018002432A2 (en)	2018-09-18
HK1252615A1 (en)	2019-05-31

Publication	Publication Date	Title
CL2018000699A1 (en)	2019-02-08	Antibodies that bind interleukin 8 (il-8) and its uses
IL263266A (en)	2018-12-31	Specific antibodies against hla-g
IL263452A (en)	2019-01-31	Anti-Ige antibodies
IL262095A (en)	2018-11-29	Anti-pacap antibodies and their use
EP3498840A4 (en)	2020-05-06	ANTI-LAG-3 ANTIBODY
DK3274370T3 (en)	2020-02-17	ANTI-CEACAM6 ANTIBODIES AND APPLICATIONS THEREOF
EP3481869A4 (en)	2020-02-26	ANTI-CD73 ANTIBODY
BR112016022385A2 (en)	2018-06-19	specific antibodies that bind to cd38 and cd3
IL254321A0 (en)	2017-11-30	A healing antibody that binds cd47
HUE066651T2 (en)	2024-08-28	Antibodies that bind CD3
CL2016002112A1 (en)	2017-06-09	Antibody molecules that bind to lag-3 and uses thereof.
PL3402821T3 (en)	2024-03-04	PSMA-BINDING ANTIBODY AND ITS APPLICATIONS
PT3354729T (en)	2024-04-11	ANTI-GARP ANTIBODY
DK3532499T3 (en)	2021-06-28	ANTI-IL-33 Antibodies and Uses thereof
DK3463435T3 (en)	2021-11-22	Alpha-synuclein antibodies and their uses
IL256099A (en)	2018-02-28	antibody
DK3359563T3 (en)	2019-09-30	ANTIGEN RECEPTORS AND APPLICATIONS THEREOF
EP3710486C0 (en)	2025-10-08	FACTOR X ANTIBODY
DK3641931T3 (en)	2021-12-13	Fluid reactor
DK3110447T3 (en)	2020-06-22	Anti-EGFR antibody and its applications
DK3245219T3 (en)	2020-06-29	GLYPICANE EPITOPES AND APPLICATIONS THEREOF
DK3368567T3 (en)	2025-10-20	HUMANIZED ANTI-DKK2 ANTIBODY AND USES THEREOF
IL275006A (en)	2020-07-30	Inspired micro-channel reactor
HRP20240195T8 (en)	2024-05-24	ANTIBODIES TO LIF AND THEIR APPLICATIONS
EP3579879A4 (en)	2020-12-16	ANTI-KIR3DL1 ANTIBODY